BE2019C547I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2019C547I2 BE2019C547I2 BE2019C547C BE2019C547C BE2019C547I2 BE 2019C547 I2 BE2019C547 I2 BE 2019C547I2 BE 2019C547 C BE2019C547 C BE 2019C547C BE 2019C547 C BE2019C547 C BE 2019C547C BE 2019C547 I2 BE2019C547 I2 BE 2019C547I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002010413 | 2002-01-18 | ||
| JP2002010447 | 2002-01-18 | ||
| PCT/JP2003/000270 WO2003062233A1 (fr) | 2002-01-18 | 2003-01-15 | Derive de 2-acylaminothiazole et son sel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2019C547I2 true BE2019C547I2 (no) | 2022-05-17 |
Family
ID=27615666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2019C547C BE2019C547I2 (no) | 2002-01-18 | 2019-11-06 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7638536B2 (no) |
| EP (2) | EP2314586B1 (no) |
| JP (2) | JP4120586B2 (no) |
| KR (1) | KR101010905B1 (no) |
| CN (1) | CN1319967C (no) |
| BE (1) | BE2019C547I2 (no) |
| CA (1) | CA2472711C (no) |
| CY (2) | CY1114169T1 (no) |
| DK (1) | DK1466912T3 (no) |
| ES (2) | ES2416304T3 (no) |
| FR (1) | FR19C1072I2 (no) |
| HU (1) | HUS1900052I1 (no) |
| LU (1) | LUC00137I2 (no) |
| NL (1) | NL301020I2 (no) |
| PT (1) | PT1466912E (no) |
| SI (1) | SI1466912T1 (no) |
| WO (1) | WO2003062233A1 (no) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI284639B (en) * | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| EP1763350B1 (en) * | 2004-07-06 | 2011-12-21 | Xenon Pharmaceuticals Inc. | Nicotinamide derivatives and their use as therapeutic agents |
| EP2314586B1 (en) * | 2002-01-18 | 2016-09-14 | Astellas Pharma Inc. | 2-Acylaminothiazole derivative or salt thereof |
| BR0308081A (pt) * | 2002-03-13 | 2004-12-21 | Janssen Pharmaceutica Nv | Inibidores de histona desacetilase |
| WO2004029049A1 (ja) * | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
| MXPA06000441A (es) | 2003-07-17 | 2006-04-05 | Astellas Pharma Inc | Derivado de 2-acilaminotiazole o sal del mismo. |
| ES2599529T3 (es) * | 2003-08-12 | 2017-02-02 | Shionogi & Co., Ltd. | Compuestos que tienen agonismo hacia el receptor de trombopoyetina |
| US7718808B2 (en) * | 2003-12-26 | 2010-05-18 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
| WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| CA2580860A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
| MX2007004765A (es) * | 2004-10-25 | 2007-07-09 | Ligand Pharm Inc | Compuestos y metodos que modulan la actividad de la trombopoyetina. |
| KR101215225B1 (ko) * | 2004-12-08 | 2012-12-26 | 닛산 가가쿠 고교 가부시키 가이샤 | 트롬보포이에틴 수용체 활성화제로서의3-에틸리덴히드라지노 치환 헤테로시클릭 화합물 |
| WO2006064957A1 (ja) | 2004-12-14 | 2006-06-22 | Nissan Chemical Industries, Ltd. | アミド化合物及びトロンボポエチンレセプター活性化剤 |
| JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| JP4665769B2 (ja) * | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
| US20100280023A1 (en) * | 2005-06-23 | 2010-11-04 | Kyowa Hakko Kogyo Co., Ltd. | Thiazole derivatives |
| WO2007036769A1 (en) * | 2005-07-05 | 2007-04-05 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
| WO2007004038A1 (en) * | 2005-07-05 | 2007-01-11 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
| AU2006267148A1 (en) * | 2005-07-13 | 2007-01-18 | Astrazeneca Ab | New pyridine analogues |
| TWI368617B (en) | 2005-07-15 | 2012-07-21 | Nissan Chemical Ind Ltd | Thiophene compounds and thrombopoietin receptor activators |
| US7960425B2 (en) | 2005-07-20 | 2011-06-14 | Nissan Chemical Industries, Ltd. | Pyrazole compounds and thrombopoietin receptor activators |
| KR101350099B1 (ko) | 2005-11-07 | 2014-01-09 | 닛산 가가쿠 고교 가부시키 가이샤 | 하이드라지드 화합물 및 트롬보포이에틴 리셉터 활성화제 |
| KR20080074166A (ko) * | 2005-11-08 | 2008-08-12 | 아스테라스 세이야쿠 가부시키가이샤 | 혈소판감소증을 치료하는 조성물 및 방법 |
| JP5157900B2 (ja) * | 2006-06-07 | 2013-03-06 | 日産化学工業株式会社 | 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
| AU2007284644B2 (en) * | 2006-08-08 | 2011-09-01 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
| JP5164510B2 (ja) * | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
| UY30915A1 (es) * | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
| BRPI0814891A2 (pt) | 2007-07-31 | 2015-08-18 | Shionogi & Co | Composição farmacêutica contendo composto oticamente ativo tendo atividade agonista de receptor de trombopoietina, e intermediário do mesmo. |
| ES2331220B1 (es) * | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
| MX2010003881A (es) * | 2007-10-09 | 2010-07-28 | Univ Pennsylvania | El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano. |
| MX2010009082A (es) * | 2008-02-25 | 2010-09-07 | Merck Patent Gmbh | Activadores de glucocinasa. |
| US8476249B2 (en) | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
| US8680150B2 (en) * | 2009-05-28 | 2014-03-25 | Ligand Pharmaceuticals, Inc. | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
| JP2013501811A (ja) * | 2009-08-14 | 2013-01-17 | エーザイ インコーポレーテッド | 血小板産生を刺激するためのｅ５５０１の使用 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) * | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JP2014144916A (ja) | 2011-08-03 | 2014-08-14 | Astellas Pharma Inc | ２−アシルアミノチアゾール化合物の結晶 |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| WO2013073577A1 (ja) | 2011-11-15 | 2013-05-23 | アステラス製薬株式会社 | ジヒドロキシ芳香族へテロ環化合物 |
| JPWO2013146754A1 (ja) * | 2012-03-27 | 2015-12-14 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体 |
| GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
| TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
| BR112015022202A2 (pt) | 2013-03-14 | 2017-07-18 | Dart Neuroscience Cayman Ltd | compostos substituídos de naftiridina e quinolina como inibidores da mao |
| WO2015002926A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| TW201506024A (zh) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物 |
| JP6319436B2 (ja) | 2014-06-06 | 2018-05-09 | アステラス製薬株式会社 | ２−アシルアミノチアゾール誘導体またはその塩 |
| RU2702106C2 (ru) * | 2014-08-26 | 2019-10-04 | Астеллас Фарма Инк. | Производное 2-аминотиазола или его соль |
| JP6658535B2 (ja) | 2014-10-31 | 2020-03-04 | 日産化学株式会社 | リガンド結合繊維及び当該繊維を用いた細胞培養基材 |
| WO2018045907A1 (zh) * | 2016-09-08 | 2018-03-15 | 四川科伦博泰生物医药股份有限公司 | 一种新型2-酰氨基噻唑衍生物及其制备方法与用途 |
| CN106749226B (zh) * | 2017-03-15 | 2019-12-20 | 广东赛拓医药科技有限公司 | 一种avatrombopag马来酸盐晶型C的制备方法 |
| CN107383000A (zh) * | 2017-08-07 | 2017-11-24 | 瑞阳制药有限公司 | 血小板增多剂的制备方法 |
| WO2020044364A1 (en) | 2018-08-27 | 2020-03-05 | Mylan Laboratories Limited | Polymorphic forms of avatrombopag maleate |
| RU2709496C1 (ru) * | 2019-08-01 | 2019-12-18 | Марат Феликсович Фазылов | Способ получения аватромбопага |
| CN110586047B (zh) * | 2019-10-08 | 2022-03-11 | 辽宁工业大学 | 一种用于吸附铅离子的改性双醛淀粉制备方法 |
| CN111620863A (zh) * | 2020-06-23 | 2020-09-04 | 苏州明锐医药科技有限公司 | 阿曲波帕的制备方法 |
| CN115057854A (zh) * | 2022-04-19 | 2022-09-16 | 河北常山生化药业股份有限公司 | 马来酸阿伐曲泊帕中间体的制备方法 |
| CN115477645A (zh) * | 2022-09-28 | 2022-12-16 | 湖南先施制药有限公司 | 马来酸阿伐曲泊帕系列杂质及其制备方法和应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5330998A (en) | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
| TW205041B (no) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
| US5256675A (en) | 1989-08-07 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same |
| JPH078863B2 (ja) | 1989-09-21 | 1995-02-01 | 久光製薬株式会社 | 新規なジフェニルチアゾール誘導体 |
| IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| JPH03199451A (ja) | 1989-12-26 | 1991-08-30 | Asahi Chem Ind Co Ltd | エアージェットルーム用筬 |
| FR2677356B1 (fr) * | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
| US5250732A (en) * | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| JP3173876B2 (ja) | 1992-06-26 | 2001-06-04 | 日本パイオニクス株式会社 | 有害ガスの検知システム |
| WO1995006635A1 (fr) | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de carbamate et medicament le contenant |
| CA2182568A1 (en) | 1994-02-10 | 1995-08-17 | Makoto Takeuchi | Novel carbamate derivative and medicinal composition containing the same |
| DE69629341T2 (de) * | 1995-03-09 | 2004-06-09 | Kyowa Hakko Kogyo Co., Ltd. | Pyrrolocarbazolderivate |
| EP0823423B1 (en) | 1995-04-28 | 2004-06-16 | Banyu Pharmaceutical Co., Ltd. | 1,4-disubstituted piperidine derivatives |
| ATE390439T1 (de) * | 1995-06-07 | 2008-04-15 | Glaxo Group Ltd | An einem thrombopoietin rezeptor bindende peptide und zusammensetzungen |
| US5963666A (en) * | 1995-08-18 | 1999-10-05 | International Business Machines Corporation | Confusion matrix mediated word prediction |
| KR980700316A (ko) * | 1995-10-17 | 1998-03-30 | 도리이 신이찌로 | 혈소판 감소증 치료제(remedies for thrombocytopenia) |
| CZ376798A3 (cs) | 1996-05-22 | 1999-04-14 | Smithkline Beecham Corporation | Nepeptidové látky podobné G-CSF |
| WO1998009967A1 (fr) | 1996-09-09 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Derives de pyrrolocarbazole |
| US5932546A (en) * | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
| US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| JPH10212289A (ja) | 1997-01-31 | 1998-08-11 | Kyowa Hakko Kogyo Co Ltd | ピロロフェナンスリジン誘導体 |
| AU9265698A (en) | 1997-09-02 | 1999-03-22 | Boehringer Mannheim Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia |
| JPH11152276A (ja) | 1997-11-20 | 1999-06-08 | Hokuriku Seiyaku Co Ltd | ベンゾジアゼピン誘導体 |
| JP2000044562A (ja) | 1998-07-31 | 2000-02-15 | Kyowa Hakko Kogyo Co Ltd | ピロロフタルイミド誘導体 |
| JP2002526482A (ja) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| ATE315390T1 (de) * | 1998-11-17 | 2006-02-15 | Smithkline Beecham Corp | Zyklische polyamine zur behandlung der thrombozytopenie |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| CA2380206A1 (en) | 1999-07-26 | 2001-02-01 | Shionogi & Co., Ltd. | Pharmaceutical compositions exhibiting thrombopoietin receptor agonism |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| AU2002222683B9 (en) | 2000-12-18 | 2021-12-23 | Institute Of Medicinal Molecular Design, Inc | Inflammatory cytokine release inhibitor |
| WO2002053160A1 (en) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating glaucoma ivb |
| WO2002062775A1 (fr) * | 2001-02-02 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivé de 2-acylaminothiazole ou son sel |
| CA2437248A1 (en) * | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
| EP2314586B1 (en) | 2002-01-18 | 2016-09-14 | Astellas Pharma Inc. | 2-Acylaminothiazole derivative or salt thereof |
| CN100525763C (zh) | 2002-03-05 | 2009-08-12 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
| WO2003084544A2 (en) | 2002-04-04 | 2003-10-16 | Cv Therapeutics, Inc. | Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| JP4635130B2 (ja) | 2002-06-11 | 2011-02-16 | 株式会社医薬分子設計研究所 | 神経変性疾患治療剤 |
| BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
| WO2004029049A1 (ja) | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
| CA2514363A1 (en) | 2003-02-12 | 2004-08-26 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| CA2523125A1 (en) * | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| MXPA06000441A (es) * | 2003-07-17 | 2006-04-05 | Astellas Pharma Inc | Derivado de 2-acilaminotiazole o sal del mismo. |
| ES2599529T3 (es) | 2003-08-12 | 2017-02-02 | Shionogi & Co., Ltd. | Compuestos que tienen agonismo hacia el receptor de trombopoyetina |
| KR20080074166A (ko) * | 2005-11-08 | 2008-08-12 | 아스테라스 세이야쿠 가부시키가이샤 | 혈소판감소증을 치료하는 조성물 및 방법 |
| AU2007284644B2 (en) | 2006-08-08 | 2011-09-01 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
-
2003
- 2003-01-15 EP EP11154632.1A patent/EP2314586B1/en not_active Expired - Lifetime
- 2003-01-15 CA CA2472711A patent/CA2472711C/en not_active Expired - Lifetime
- 2003-01-15 US US10/500,964 patent/US7638536B2/en active Active
- 2003-01-15 ES ES03700571T patent/ES2416304T3/es not_active Expired - Lifetime
- 2003-01-15 DK DK03700571.7T patent/DK1466912T3/da active
- 2003-01-15 CN CNB038044579A patent/CN1319967C/zh not_active Expired - Lifetime
- 2003-01-15 PT PT37005717T patent/PT1466912E/pt unknown
- 2003-01-15 EP EP03700571.7A patent/EP1466912B1/en not_active Expired - Lifetime
- 2003-01-15 WO PCT/JP2003/000270 patent/WO2003062233A1/ja active Application Filing
- 2003-01-15 KR KR1020047010846A patent/KR101010905B1/ko active IP Right Grant
- 2003-01-15 ES ES11154632.1T patent/ES2610611T3/es not_active Expired - Lifetime
- 2003-01-15 SI SI200332274T patent/SI1466912T1/sl unknown
- 2003-01-15 JP JP2003562111A patent/JP4120586B2/ja not_active Expired - Lifetime
-
2008
- 2008-02-04 JP JP2008023950A patent/JP4844574B2/ja not_active Expired - Lifetime
-
2009
- 2009-11-10 US US12/615,968 patent/US8338429B2/en not_active Expired - Lifetime
- 2009-11-10 US US12/615,979 patent/US20100222329A1/en not_active Abandoned
-
2012
- 2012-11-15 US US13/677,520 patent/US8765764B2/en not_active Expired - Lifetime
-
2013
- 2013-07-24 CY CY20131100629T patent/CY1114169T1/el unknown
-
2019
- 2019-11-06 BE BE2019C547C patent/BE2019C547I2/fr unknown
- 2019-11-12 LU LU00137C patent/LUC00137I2/fr unknown
- 2019-12-06 FR FR19C1072C patent/FR19C1072I2/fr active Active
- 2019-12-11 NL NL301020C patent/NL301020I2/nl unknown
- 2019-12-11 HU HUS1900052C patent/HUS1900052I1/hu unknown
- 2019-12-17 CY CY2019045C patent/CY2019045I1/el unknown